Regulus Therapeutics (United States)
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Regulus Therapeutics (United States), United States, covering academic research published from 2008 to 2024. Read More.
Open Access Percentage
52%
Total
Publications
168
Total Open
Publications
87
Total
Citations
22K
Open Access
Percentage
52%
Total
Publications
168
Total Open
Publications
87
Total
Citations
22K
Breakdown
Publisher Open
17%
Both
25%
Other Platform Open
10%
Closed
48%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 36%
25
Hybrid 18%
12
No Guarantees 46%
32
Other Platform Open
Domain 52%
32
Other Internet 41%
25
Institution 28%
17
Preprint 7%
4
Public 5%
3
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 32 |
DOI | Other Internet | 25 |
bioRxiv | Preprint | 4 |
Harvard University | Institution | 3 |
Figshare | Public | 3 |
California Institute of Technology | Institution | 2 |
Washington University in St. Louis | Institution | 1 |
University of Southern Denmark | Institution | 1 |
University of Siena | Institution | 1 |
University of Milan | Institution | 1 |